Switzerland-based biopharmaceutical Actelion Ltd. recently announced plans to start a biotech separate from the main company. Targeted to “undertake the clinical development of its non-core compounds,” the startup will be led by Actelion’s former chief medical officer as part of a management restructuring.

According to Actelion, “its first drug Tracleer®, an orally available dual endothelin receptor antagonist,” was approved as a therapy for pulmonary arterial hypertension and is marketed in nations throughout the world, including Australia, Canada, European Union member states, Japan, Switzerland, and United States. Founded in 1997, Actelion is devoted to “science related to the endothelium—the single layer of cells separating every blood vessel from the blood stream.” See Actelion Press Release, June 7, 2011; InPharm, June 20, 2011.